Stay updated on CAMMA 2 Clinical Trial - Cevostamab in BCMA-Exposed Myeloma
Sign up to get notified when there's something new on the CAMMA 2 Clinical Trial - Cevostamab in BCMA-Exposed Myeloma page.

Latest updates to the CAMMA 2 Clinical Trial - Cevostamab in BCMA-Exposed Myeloma page
- Check4 days agoChange DetectedNew entries for Contacts/Locations and Study Status were added to the record history, with the latest version count updated to 37. An earlier version dated 2026-02-09 was removed from the history.SummaryDifference0.3%

- Check11 days agoNo Change Detected
- Check19 days agoChange DetectedThe page’s revision/version indicator has been updated from v3.5.2 to v3.5.3, indicating a software or interface update rather than a modification to the clinical trial record content.SummaryDifference0.1%

- Check27 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0 from the history list.SummaryDifference0.1%

- Check48 days agoChange DetectedThe record history now includes more version entries, with additions and deletions color-coded to show edits to Study Status and Contacts/Locations.SummaryDifference0.1%

- Check55 days agoChange DetectedRevision v3.5.0 was added and Revision v3.4.3 was removed from the history list.SummaryDifference0.1%

- Check69 days agoChange DetectedThe history now includes revision v3.4.3 and excludes v3.4.2.SummaryDifference0.1%

Stay in the know with updates to CAMMA 2 Clinical Trial - Cevostamab in BCMA-Exposed Myeloma
Enter your email address, and we'll notify you when there's something new on the CAMMA 2 Clinical Trial - Cevostamab in BCMA-Exposed Myeloma page.